Evidence map›Paper›PMID 24894817›Full record

ArticleScientific reports2014

Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity.

Kyle K L Phua, Herman F Staats, Kam W Leong, Smita K Nair

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Applications of mRNA Delivery in Cancer Immunotherapy.International journal of nanomedicine · 2025
    Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Lipid carriers for mRNA delivery.Acta pharmaceutica Sinica. B · 2023
    Review
  14. Aerosol pulmonary immune engineering.Advanced drug delivery reviews · 2023
    Review
  15. Article
  16. Review
  17. Review
  18. mRNA cancer vaccines: Advances, trends and challenges.Acta pharmaceutica Sinica. B · 2022
    Review
  19. Review
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kyle K L Phua1] Department of Biomedical Engineering, Duke University, USA [2] Department of Chemical & Biomolecular Engineering, National University of Singapore, Singapore.
Herman F StaatsDepartment of Pathology, Duke University Medical Center, USA.
Kam W Leong1] Department of Biomedical Engineering, Duke University, USA [2] Department of Surgery, Duke University Medical Center, USA.
Smita K NairDepartment of Surgery, Duke University Medical Center, USA.

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8M
NCI NIH HHS P30 CA014236
6 · The paper itself

Abstract

Direct in vivo administration of messenger RNA (mRNA) delivered in both naked and nanoparticle formats are actively investigated because the use of dendritic cells transfected ex vivo with mRNA for cancer therapy is expensive and needs significant infrastructure. Notably, intravenous and subcutaneous injections are the only routes of administration tested for mRNA nanoparticle tumor vaccination. In this report, we demonstrate that tumor immunity can be achieved via nasal administration of mRNA. Mice nasally immunized with mRNA delivered in nanoparticle format demonstrate delayed tumor progression in both prophylactic and therapeutic immunization models. The observed tumor immunity correlates with splenic antigen-specific CD8+ T cells and is achieved only when mRNA is delivered in nanoparticle but not in naked format. In conclusion, we demonstrate, as a proof-of-concept, a non-invasive approach to mRNA tumor vaccination, increasing its potential as a broadly applicable and off-the-shelf therapy for cancer treatment.

Indexed as

Administration, IntranasalAnimalsCancer VaccinesCell Line, TumorCell SurvivalDrug CompoundingFemaleMiceMice, Inbred C57BLNanoparticlesNeoplasms, ExperimentalRNA, MessengerTreatment OutcomeCancer VaccinesRNA, Messenger

Identifiers

PMID24894817
PMCPMC4044635

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.